Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa: Efficacy, Safety, and Economic Assessments

Highlights

• Adalimumab remains the dominant cost-efficient biologic for moderate-to-severe hidradenitis suppurativa (HS) across multiple international health systems.
• Bimekizumab demonstrates superior or comparable clinical efficacy versus other biologics, notably IL-17 inhibitors, with durable long-term benefits and favorable safety profiles.
• Secukinumab shows sustained efficacy up to two years with robust safety, though cost-effectiveness varies by region due to pricing variability.
• Mechanistic studies highlight dual IL-17A/IL-17F blockade as a promising therapeutic strategy, reflecting HS pathogenesis complexity involving neutrophilic inflammation.

Background